ASHP Supports Reauthorization of Lorna Breen Act

Published: February 14, 2024
United States Capitol Building

Today, ASHP urged Congress to reauthorize the Dr. Lorna Breen Health Care Provider Protection Act (H.R. 7153) to sustain and expand the landmark legislation’s impact on healthcare workers’ mental health and well-being.

Since its passage in 2022, the bipartisan Breen act has funded $103 million for evidence-based initiatives to support healthcare workers, including the ASHP Well-Being Ambassador program. ASHP’s vice president of government relations, Tom Kraus, sent a letter in support of the legislation to the House Energy and Commerce Committee’s Subcommittee on Health, which held a hearing Wednesday on the Breen Act and other proposals aimed at helping patients and their caregivers.

The ASHP Well-Being program has reached over 4,300 pharmacists, pharmacy technicians, pharmacy residents, and student pharmacists through a curriculum-based, virtual learning community aimed at mitigating occupational burnout and creating cultures of well-being in healthcare organizations, Kraus said in the letter.

The Dr. Lorna Breen Health Care Provider Protection Act is sponsored in the House by Reps. Susan Wild (D-PA), Earl “Buddy” Carter (R-GA), Debbie Dingell (D-MI), and Jen Kiggans (D-VA). ASHP also sent a letter of support to the sponsors of the Senate version (S. 3679), Senators Tim Kaine (D-VA) and Todd Young (R-IN).

Use this action alert to ask your members of Congress to reauthorize this crucial legislation.

Posted February 14, 2024

Advance Your Professional Development

View Other Products

Free Board Exam Prep Resources

The Review & Recertification Reward Program (RRRP) includes free access to exam preparation material + enrollment in a recertification plan billed monthly ($10) during your initial recertification cycle. For ASHP members only.

Learn More
Review & Recertification Reward Program (RRRP)

New Edition Available to Order

AHFS Drug Information® 2024 contains the most dependable drug information available—all in one place. It is the most comprehensive evidence-based source of drug information complete with therapeutic guidelines and off-label uses.

Order Today
AHFS 2024 Drug Information